BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 35864351)

  • 1. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
    Chen BB; Liang PC; Shih TT; Liu TH; Shen YC; Lu LC; Lin ZZ; Hsu C; Hsu CH; Cheng AL; Shao YY
    Eur Radiol; 2023 Jan; 33(1):512-522. PubMed ID: 35864351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
    Liu M; Jin Q; Wang H; Li Y
    Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.
    Deng GM; Song HB; Du ZZ; Xue YW; Song HJ; Li YZ
    World J Gastroenterol; 2024 Feb; 30(8):863-880. PubMed ID: 38516238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study.
    Bannangkoon K; Hongsakul K; Tubtawee T; Ina N; Chichareon P
    Sci Rep; 2023 Mar; 13(1):3978. PubMed ID: 36894658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.
    Rollins KE; Tewari N; Ackner A; Awwad A; Madhusudan S; Macdonald IA; Fearon KC; Lobo DN
    Clin Nutr; 2016 Oct; 35(5):1103-9. PubMed ID: 26411749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.
    Iritani S; Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Suetsugu A; Shiraki M; Shimizu M; Moriwaki H
    J Gastroenterol; 2015 Mar; 50(3):323-32. PubMed ID: 24817668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
    Xu MC; Huelster HL; Hatcher JB; Avulova S; Stocks BT; Glaser ZA; Moses KA; Silver HJ
    J Urol; 2021 Mar; 205(3):800-805. PubMed ID: 33080148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy.
    Peng YC; Wu CH; Tien YW; Lu TP; Wang YH; Chen BB
    Eur Radiol; 2021 Apr; 31(4):2472-2481. PubMed ID: 32974690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.
    Akce M; Liu Y; Zakka K; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT; Bilen MA; El-Rayes BF
    Am J Clin Oncol; 2021 Feb; 44(2):74-81. PubMed ID: 33350681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of sarcopenia and myosteatosis on postoperative outcomes and 5-year survival in curatively operated colorectal cancer patients - A retrospective register study.
    Aro R; Mäkäräinen-Uhlbäck E; Ämmälä N; Rautio T; Ohtonen P; Saarnio J; Meriläinen S
    Eur J Surg Oncol; 2020 Sep; 46(9):1656-1662. PubMed ID: 32224072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of sarcopenia and myosteatosis in trans-arterial (chemo)-embolization treated HCC patients.
    Long J; Zhang X; Mi W; Shi J; Ren H; Wang Q
    Aging (Albany NY); 2024 Jan; 16(1):389-401. PubMed ID: 38189812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myosteatosis, the More Significant Predictor of Outcome: An Analysis of the Impact of Myosteatosis, Sarcopenia, and Sarcopenic Obesity on Liver Transplant Outcomes in Johannesburg, South Africa.
    Irwin NEA; Fabian J; Hari KR; Lorentz L; Mahomed A; Botha JF
    Exp Clin Transplant; 2021 Sep; 19(9):948-955. PubMed ID: 34387151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.
    Dong D; Shi JY; Shang X; Liu B; Xu WL; Cui GZ; Wang NY
    Medicine (Baltimore); 2022 Feb; 101(5):e28680. PubMed ID: 35119010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
    Kim DW; Ahn H; Kim KW; Lee SS; Kim HJ; Ko Y; Park T; Lee J
    Korean J Radiol; 2022 Nov; 23(11):1055-1066. PubMed ID: 36098341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep learning-based assessment of CT markers of sarcopenia and myosteatosis for outcome assessment in patients with advanced pancreatic cancer after high-intensity focused ultrasound treatment.
    Nowak S; Kloth C; Theis M; Marinova M; Attenberger UI; Sprinkart AM; Luetkens JA
    Eur Radiol; 2024 Jan; 34(1):279-286. PubMed ID: 37572195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia impairs survival in patients with potentially curable hepatocellular carcinoma.
    Levolger S; van Vledder MG; Muslem R; Koek M; Niessen WJ; de Man RA; de Bruin RW; Ijzermans JN
    J Surg Oncol; 2015 Aug; 112(2):208-13. PubMed ID: 26266324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90 radioembolization for hepatocellular carcinoma: Outcome prediction with MRI derived fat-free muscle area.
    Faron A; Sprinkart AM; Pieper CC; Kuetting DLR; Fimmers R; Block W; Meyer C; Thomas D; Attenberger U; Luetkens JA
    Eur J Radiol; 2020 Apr; 125():108889. PubMed ID: 32087468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different computed tomography parameters for defining myosteatosis in patients with advanced non-small cell lung cancer.
    Zhang W; Tang J; Tang H; Xie L; Wang J; Wu J; Yang M
    Clin Nutr; 2023 Dec; 42(12):2414-2421. PubMed ID: 37871482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcopenic obesity and its relation with muscle quality and mortality in patients on chronic hemodialysis.
    Sabatino A; Avesani CM; Regolisti G; Adinolfi M; Benigno G; Delsante M; Fiaccadori E; Gandolfini I
    Clin Nutr; 2023 Aug; 42(8):1359-1368. PubMed ID: 37418843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.